グルコキナーゼのアロステル活性化剤:糖尿病治療における潜在的な役割

Joseph Grimsby¹, Ramakanth Sarabu, Wendy L Corbett

¹Department of Metabolic Diseases, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA.

Science (New York, N.Y.)

|July 19, 2003

まとめ

グルコースキナーゼ活性化剤 (GKA) は,2型糖尿病の管理に新しいアプローチを提供します. これらの薬剤は,グルコース代謝とインスリン分泌を促進し,糖尿病モデルの血糖値を下げます.

科学分野:

バイオケミストリーバイオケミストリー
エンドクリノロジーエンドクリノロジー
薬理学薬理学とは

背景:

グルコースキナーゼ (GK) は,胰腺ベータ細胞と肝細胞におけるグルコースリン酸化を調節し,グルコースホメオスタシスに不可欠である.
機能不全のGKは,2型糖尿病 (T2DM) に関わっている.

研究の目的:

非必須の混合型グルコキナーゼ活性化剤 (GKA) の新種を潜在的な抗糖尿病剤として調査する.
グルコース代謝とインスリン分泌の改善におけるGKAの有効性を評価する.

主な方法:

グルコースアミノ酸の作用機構の特徴,グルコース親和度およびVmaxへの影響を含む.
単離されたネズミの小島における肝臓のグルコース代謝とグルコース刺激によるインスリン分泌に対するGKAの影響の評価.
T2DMのネズミのモデルにおけるGKAsの評価,血糖,グルコース耐性,および肝臓のグルコース吸収のモニタリング.

主要な成果:

GKAsは,非必須の混合型活性化剤として特定され,GKのグルコース親和性とVmaxの両方を増加させました.
GKAは肝臓のグルコース代謝と,臓の小島からインスリン分泌を強めた.
ネズミのT2DMモデルでは,GKAは血糖値を大幅に低下させ,グルコース耐性を改善し,肝臓のグルコース吸収を増加させた.

結論:

非必須の混合型GKAは,T2DMの治療の可能性を示しています.
これらの薬剤は,肝臓と臓に併せて作用することで,グルコースホメオスタシスを効果的に調節します.
GKAは,新しい糖尿病の薬物療法を開発するための有望な道を示しています.

さらに関連する動画

06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

関連する概念動画

01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

関連する実験動画